英诺特跌2.00%，成交额1.13亿元，主力资金净流出1386.18万元

Core Viewpoint - Innotech's stock price has shown significant volatility, with a recent decline of 2.00% and a total market capitalization of 5.027 billion yuan, despite a year-to-date increase of 21.60% [1] Group 1: Stock Performance - As of January 13, Innotech's stock price is 36.70 yuan per share, with a trading volume of 113 million yuan and a turnover rate of 4.36% [1] - The stock has increased by 18.81% over the last five trading days, 17.93% over the last 20 days, and 22.01% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Innotech reported a revenue of 330 million yuan, a year-on-year decrease of 36.56%, and a net profit attributable to shareholders of 131 million yuan, down 46.37% year-on-year [2] Group 3: Shareholder Information - As of September 30, 2025, Innotech has 8,037 shareholders, an increase of 10.57% from the previous period, with an average of 8,627 circulating shares per shareholder, a decrease of 8.86% [2] - The company has distributed a total of 152 million yuan in dividends since its A-share listing [3] - The medical device ETF (159883) is among the top ten circulating shareholders, holding 498,000 shares as a new shareholder [3] Group 4: Company Overview - Innotech, established on February 6, 2006, and listed on July 28, 2022, specializes in the research, production, and sales of POCT rapid diagnostic products [1] - The company's main revenue sources include respiratory series (96.49%), other reagent series (2.99%), and preconception care series (0.51%) [1] - Innotech operates within the pharmaceutical and biotechnology sector, specifically in medical devices and in vitro diagnostics [1]